TY - JOUR
T1 - Lethal Capecitabine Toxicity in Patients With Complete Dihydropyrimidine Dehydrogenase Deficiency Due to Ultra-Rare DPYD Variants
AU - van Kuilenburg, André B P
AU - Pleunis-van Empel, Marjolein C H
AU - Brouwer, Rick B
AU - Sijben, Angelique E J
AU - Knapen, Daan G
AU - Oude Munnink, Thijs H
AU - van Zanden, Jelmer J
AU - Janssens-Puister, Jenny
AU - Dobritzsch, Doreen
AU - Meinsma, Rutger
AU - Meijer-Jansen, Judith
AU - van Dooren, Silvy J M
AU - Vijzelaar, Raymon
AU - Pop, Ana
AU - Salomons, Gajja S
AU - Maring, Jan Gerard
AU - Niezen-Koning, Klary E
PY - 2024/5/6
Y1 - 2024/5/6
N2 - A DPD deficiency should be considered in case of severe toxicity even in the absence of common risk variants in DPYD.
AB - A DPD deficiency should be considered in case of severe toxicity even in the absence of common risk variants in DPYD.
KW - Humans
KW - Dihydropyrimidine Dehydrogenase Deficiency/genetics
KW - Capecitabine/adverse effects
KW - Dihydrouracil Dehydrogenase (NADP)/genetics
KW - Antimetabolites, Antineoplastic/adverse effects
KW - Male
KW - Female
KW - Fatal Outcome
KW - Middle Aged
U2 - 10.1200/PO.23.00599
DO - 10.1200/PO.23.00599
M3 - Article
C2 - 38709992
SN - 2473-4284
VL - 8
JO - JCO Precision Oncology
JF - JCO Precision Oncology
M1 - e2300599
ER -